Trials / Completed
CompletedNCT00600782
Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region
Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 21 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) | Intramuscular injection, 2 doses at 0, 1 month |
Timeline
- Start date
- 2008-02-05
- Primary completion
- 2008-12-19
- Completion
- 2008-12-19
- First posted
- 2008-01-25
- Last updated
- 2020-10-12
Locations
1 site across 1 country: South Africa
Source: ClinicalTrials.gov record NCT00600782. Inclusion in this directory is not an endorsement.